Allogene Therapeutics (ALLO) Receivables (2020)

Allogene Therapeutics (ALLO) posted Receivables of $3.1 million for Q3 2020, up 287.5% sequentially from $800000.0 in Q2 2020.

Analysis

Allogene Therapeutics (ALLO) Receivables (2020) Analysis & Trends

Allogene Therapeutics has reported Receivables for 1 years, with the latest figure at $3.1 million in Q3 2020.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	1.93 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	160.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	1.06 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	912.74 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	215.33 Mn
10	Allogene Therapeutics	647.99 Mn	647.99 Mn	-	-

Historic Data

Download Data